D-0091-2022 Class III Terminated
FDA drug recall D-0091-2022 was initiated by Lupin Pharmaceuticals Inc. on Oct 20, 2021 and is designated Class III. Reason for recall: Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration. The recall status is terminated (terminated Aug 23, 2022). Affected quantity: 16,272 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 3, 2021
- Initiation Date
- Oct 20, 2021
- Termination Date
- Aug 23, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 16,272 bottles
Product description
Gatifloxacin Ophthalmic Solution, 0.5%, 2.5 mL bottle, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, INDIA, NDC 68180-435-01.
Reason for recall
Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.
Distribution pattern
Nationwide in the USA and Puerto Rico
Code information
Lot # H002512, exp. date March 2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0091-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026